World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 6, Number 1, February 2015, pages 265-269

Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy

Tables

**Table 1.** Patient Characteristics Prior to and at the Time of Diagnosis of Liver Metastasis
Characteristic	N
Median age	68.5 (59 - 81)
ECOG performance status	1 (3), 2 (3)
Gleason score	8 (2), 9 (2), unknown (2)
Median PSA at diagnosis of prostate cancer	149
Chemotherapy given prior to liver metastasis	None
Median time to development of liver metastasis	15.5 months
PSA at the time of liver metastasis	100.5
Hemoglobin	9.95 (7.4 - 14)
Alkaline phosphatase	233.5 (59 - 524)
AST	72 (24 - 170)
ALT	46.5 (12 - 79)
Albumin	3.8 (3.2 - 4.2)
Metastasis to other sites	Lung (2), bone (3), none (3)

**Table 2.** Pathological Analysis of Liver Metastasis
IHC	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Chromogranin-A	Negative	Negative	Negative	Negative	N/A	Negative
Synaptophysin	Negative	Negative	Negative	Negative	N/A	Focally positive
CD56	Negative	Negative	Negative	Negative	N/A	Negative
CK7	Negative	Negative	Negative	Negative	N/A	N/A
CK20	Negative	Negative	Rare positive	Negative	N/A	N/A
TTF-1	Negative	Negative	Negative	Negative	N/A	N/A
PSMA	Positive	Negative	Positive	Positive	N/A	Positive
PSA	Negative	Positive	Negative	Negative	N/A	Positive
Final histology	Adeno CA	Adeno CA	Adeno CA	Adeno CA	N/A	Adeno CA

**Table 3.** Outcome of Patients Treated With Hormone
Treatment characteristics	No. of patients	Response
Lupron + casodex who presented with liver metastasis	2/2	Expired in less than 3 months
Zytiga (Ab) after taxotere	2/3	Progression
Progress on LA then on xtandi (enzalutamide)	1/6	Stable disease

**Table 4.** Treatment With Chemotherapy
Treatment characteristics: chemotherapy	Number of patients
Chemotherapy after liver metastasis (taxotere)	3 (four cycles ranging from three to six cycles)
PSA drop after taxotere	> 50% (2), > 90% (1)
Total survival from diagnosis of prostate cancer	3.25 years
Survival after liver metastasis	4 months